Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-Olinciguat PK and Mass Balance Study in Healthy Males
NCT03795519Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olinciguat in sickle cell disease (SCD) and achalasia, sponsored by Cyclerion Therapeutics. Primary endpoints: Amount of total radioactivity excreted in urine (Aeu) and feces (Aef), Cumulative Aeu and cumulative Aef and 10 more. Started Jan 2019; status: completed.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)achalasia
Beyond the preview
Go deeper on NCT03795519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795519.